Diagnosing Infectious Mononucleosis

Initial Testing Approach

The Infectious Diseases Society of America recommends starting with a complete blood count with differential and a rapid heterophile antibody test, but if the heterophile test is negative and clinical suspicion remains high, proceed directly to EBV-specific antibody testing with VCA IgM, VCA IgG, and EBNA antibodies 1, 2
The heterophile antibody typically becomes detectable between days 6-10 after symptom onset and peaks during weeks 2-3 of illness 1

False-negative results occur in approximately 10% of patients and are especially common in children younger than 10 years 1, 2
False-positive results can occur with leukemia, pancreatic carcinoma, viral hepatitis, and CMV infection 1

The Infectious Diseases Society of America explicitly states that Paul-Bunnell and Monospot tests are suboptimal for diagnosis, and recommends EBV-specific antibody testing when these are negative 3, 4
VCA IgM antibodies indicate acute/recent infection 1, 2
VCA IgG antibodies develop rapidly in acute infection 1, 2
EBNA antibodies are critical for timing the infection 1, 2

Primary acute EBV infection is diagnosed when VCA IgM is positive and EBNA antibodies are absent 1, 2
Past infection is indicated when EBNA antibodies are present 1, 2
EBNA antibodies develop 1-2 months after primary infection and persist for life 1
Over 90% of normal adults have IgG antibodies to VCA and EBNA from past infection 1

Quantitative EBV viral load testing by nucleic acid amplification is recommended for suspected EBV-associated lymphoproliferative disease in immunocompromised patients 2
Post-transplant patients require EBV DNA surveillance due to high risk of lymphoproliferative disease 3, 4

Do not rely solely on heterophile testing in children under 10 years - proceed directly to EBV-specific antibodies 1, 2
Do not order EBV testing from throat swabs - EBV can persist in throat secretions for weeks to months after infection and does not confirm acute infection 2
Consider alternative diagnoses including CMV, adenovirus, HIV, and Toxoplasma gondii when evaluating mononucleosis-like illness 1, 2

The American Journal of Hematology suggests that markedly elevated VCA IgG titers (≥1:640) combined with elevated EA IgG (≥1:160) may indicate Chronic Active EBV Infection (CAEBV), particularly when accompanied by persistent infectious mononucleosis-like symptoms and positive IgA antibodies to VCA and/or EA 5
The presence of VCA IgG without additional context (IgM status, EBNA status) cannot be used to distinguish between recent and remote infection, highlighting the importance of comprehensive testing 5

No facts are available in this section as all relevant information was either not cited or was marked to be ignored.

The Infectious Diseases Society of America recommends ordering EBV-specific antibody testing, including VCA IgM, VCA IgG, and EBNA, when clinical suspicion for infectious mononucleosis remains high despite a negative Monospot test, and CMV testing should be included in the workup of FUO as it represents a common cause of mononucleosis-like syndromes 6

Approximately 5-10% of EBV-infected patients fail to develop EBNA antibodies, which should be considered when interpreting results 6

Mononucleosis-like syndromes (including both EBV and CMV) account for 0.8% of fever cases in returning travelers, representing a significant diagnostic category 7
False-positive CMV IgM results can occur in patients infected with EBV, highlighting the importance of testing both simultaneously to avoid diagnostic confusion 6
For immunocompetent patients with suspected acute CMV infection, CMV-specific IgM and IgG antibody testing is recommended as the first-line diagnostic test 6

For immunocompromised patients, order quantitative EBV and CMV viral load testing by nucleic acid amplification (NAAT) rather than relying solely on serology 6
These patients are at high risk for EBV-associated lymphoproliferative disease, which requires viral load monitoring 6